Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
March 20, 2006
- Bill to Amend PAL Approved by Cabinet
March 20, 2006
- Kowa, Nikken Chemicals to Integrate Operations on Oct. 1
March 20, 2006
- SELF-MEDICATION NEWS IN BRIEF
March 20, 2006
- Explanatory Meeting on JapicCTI
March 13, 2006
- ＜JCROA Seminar＞Collaborative Int'l Trials Remain Risky: Dr Iwasaki of EFPIA
March 13, 2006
- GENERICS NEWS IN BRIEF
March 13, 2006
- R&D NEWS IN BRIEF
March 13, 2006
- Eisai Aims at \1 Tril. Sales in FY2011
March 13, 2006
- SELF-MEDICATION NEWS IN BRIEF
March 13, 2006
- Mr Iwasaki to Implement Reform through Dialogues with Employees: Pfizer
March 13, 2006
- OPINION
March 13, 2006
- Takeda Promoting Basen OD Tables to Win Market Competition
March 13, 2006
- JPA Holds 100th Assembly of House of Delegates
March 13, 2006
- Norvasc Was Most-prescribed Drug in 2005: IMS Japan
March 13, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 13, 2006
- Bushu Pharm. Starts Up New Lines for Biotech Drugs
March 13, 2006
- MEDICAL DEVICE NEWS IN BRIEF
March 13, 2006
- BUSINESS NEWS IN BRIEF
March 13, 2006
- New Prescription Form Will Not Increase Use of Generics Much: Apo Plus Station
March 13, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…